Movement Alert｜Bristol-Myers Squibb Falls 3.19% in Regular Trading, Broad Pharma Sector Weakness Amid Q2 Pricing Power Concerns

Market Focus07-15 03:35

On July 15, Bristol-Myers Squibb declined 3.19% in regular trading, trading at $57.32/share, with turnover of $403 million. The stock fell alongside a broadly weak pharmaceutical sector.

The decline came amid heightened investor concerns about biopharma pricing power heading into Q2 earnings season. Bank of America recently highlighted loss-of-exclusivity headwinds as a key risk for companies like Bristol-Myers Squibb, lowering its price target to $66 from $67. The analysts noted that companies facing patent cliffs continue to underperform peers with cleaner growth outlooks.

Within the Pharmacy sector, the overall performance was weak. Among individual stocks, Eli Lilly fell 2.3%, Johnson & Johnson fell 1.7%, Merck fell 2.84%, Pfizer fell 1.08%, and AstraZeneca fell 2.68%. The company is scheduled to report Q2 earnings on July 30, with consensus EPS expectations of $1.61.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144615628?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 03:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144615628","market":"us","top_or_hot":-1,"title":"Movement Alert｜Bristol-Myers Squibb Falls 3.19% in Regular Trading, Broad Pharma Sector Weakness Amid Q2 Pricing Power Concerns","media":"Market Focus","content":"<p><p>On July 15, Bristol-Myers Squibb declined 3.19% in regular trading, trading at $57.32/share, with turnover of $403 million. The stock fell alongside a broadly weak pharmaceutical sector.</p><p>The decline came amid heightened investor concerns about biopharma pricing power heading into Q2 earnings season. Bank of America recently highlighted loss-of-exclusivity headwinds as a key risk for companies like Bristol-Myers Squibb, lowering its price target to $66 from $67. The analysts noted that companies facing patent cliffs continue to underperform peers with cleaner growth outlooks.</p><p>Within the Pharmacy sector, the overall performance was weak. Among individual stocks, Eli Lilly fell 2.3%, Johnson & Johnson fell 1.7%, Merck fell 2.84%, Pfizer fell 1.08%, and AstraZeneca fell 2.68%. The company is scheduled to report Q2 earnings on July 30, with consensus EPS expectations of $1.61.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Bristol-Myers Squibb Falls 3.19% in Regular Trading, Broad Pharma Sector Weakness Amid Q2 Pricing Power Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Bristol-Myers Squibb Falls 3.19% in Regular Trading, Broad Pharma Sector Weakness Amid Q2 Pricing Power Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 03:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, Bristol-Myers Squibb declined 3.19% in regular trading, trading at $57.32/share, with turnover of $403 million. The stock fell alongside a broadly weak pharmaceutical sector.</p><p>The decline came amid heightened investor concerns about biopharma pricing power heading into Q2 earnings season. Bank of America recently highlighted loss-of-exclusivity headwinds as a key risk for companies like Bristol-Myers Squibb, lowering its price target to $66 from $67. The analysts noted that companies facing patent cliffs continue to underperform peers with cleaner growth outlooks.</p><p>Within the Pharmacy sector, the overall performance was weak. Among individual stocks, Eli Lilly fell 2.3%, Johnson & Johnson fell 1.7%, Merck fell 2.84%, Pfizer fell 1.08%, and AstraZeneca fell 2.68%. The company is scheduled to report Q2 earnings on July 30, with consensus EPS expectations of $1.61.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMY","symbol_name":"施贵宝","start_time":0,"source_url":"","article_id":"1144615628","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144615628","pubTimestamp":1784057716,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, Bristol-Myers Squibb declined 3.19% in regular trading, trading at $57.32/share, with turnover of $403 million. The stock fell alongside a broadly weak pharmaceutical sector.The decline...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BMY":"施贵宝"},"translate_title":"走势警报|百时美施贵宝常规交易下跌 3.19%，第二季度定价权担忧导致制药行业整体疲软","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":1},"content_text":"On July 15, Bristol-Myers Squibb declined 3.19% in regular trading, trading at $57.32/share, with turnover of $403 million. The stock fell alongside a broadly weak pharmaceutical sector.The decline came amid heightened investor concerns about biopharma pricing power heading into Q2 earnings season. Bank of America recently highlighted loss-of-exclusivity headwinds as a key risk for companies like Bristol-Myers Squibb, lowering its price target to $66 from $67. The analysts noted that companies facing patent cliffs continue to underperform peers with cleaner growth outlooks.Within the Pharmacy sector, the overall performance was weak. Among individual stocks, Eli Lilly fell 2.3%, Johnson & Johnson fell 1.7%, Merck fell 2.84%, Pfizer fell 1.08%, and AstraZeneca fell 2.68%. The company is scheduled to report Q2 earnings on July 30, with consensus EPS expectations of $1.61.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144615628","isCrawlerRequest":true}